The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II trial to evaluate cabozantinib in patients with advanced hepatocellular carcinoma with Child-Pugh class B cirrhosis after first-line therapy.
 
Thomas Enzler
No Relationships to Disclose
 
Neehar Parikh
No Relationships to Disclose
 
Chih-Yi Liao
Consulting or Advisory Role - Exelixis; Incyte; Ipsen; Lexicon
Speakers' Bureau - Eisai; Exelixis
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Eisai; Exelixis; Incyte; Ipsen
 
Aparna Kalyan
No Relationships to Disclose
 
David Hsieh
No Relationships to Disclose
 
Kent A. Griffith
No Relationships to Disclose
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Celgene; Halozyme; Incyte; Ipsen; Klus Pharma; Newlink Genetics; QED Therapeutics
Research Funding - Agios (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); FibroGen (Inst); Halozyme (Inst); Incyte (Inst); Ipsen (Inst); MedImmune (Inst); Rafael Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ASCO; FibroGen; FibroGen